Search | VHL Regional Portal

BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer.

Ehmsen, Sidse; Pedersen, Rune M; Bang, Line L; Asmussen, Anders; Kragh, Amalie; Holm, Dorte K; Sydenham, Thomas V; Jensen, Thøger G; Jeppesen, Stefan S; Frederiksen, Henrik; Andersen, Thomas E; Ditzel, Henrik J.

Cancer Cell ; 41(4): 649-650, 2023 04 10.

Article in English | MEDLINE | ID: mdl-36804967

ABSTRACT

Ehmsen et al. evaluate the neutralizing capacity to current SARS-CoV-2 variants in patients with cancer before and after receiving the BNT162b2 bivalent mRNA vaccine booster. Bivalent vaccine provides some protection against BQ.1.1 but fails to protect against XBB.1 and XBB.1.5 in patients with cancer.

Subject(s)

COVID-19 , Neoplasms , Humans , COVID-19/prevention & control , SARS-CoV-2/genetics , BNT162 Vaccine , Neoplasms/genetics , Neoplasms/therapy , RNA, Messenger/genetics

Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer.

Ehmsen, Sidse; Asmussen, Anders; Jeppesen, Stefan S; Nilsson, Anna Christine; Kragh, Amalie; Frederiksen, Henrik; Ditzel, Henrik J.

Cancer Cell ; 40(8): 800-801, 2022 08 08.

Article in English | MEDLINE | ID: mdl-35803259

Subject(s)

COVID-19 , Neoplasms , COVID-19/prevention & control , COVID-19 Vaccines , Humans , RNA, Messenger , Vaccination

Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination.

Ehmsen, Sidse; Asmussen, Anders; Jeppesen, Stefan S; Nilsson, Anna Christine; Østerlev, Sabina; Kragh, Amalie; Frederiksen, Henrik; Ditzel, Henrik J.

Cancer Cell ; 40(4): 338-339, 2022 04 11.

Article in English | MEDLINE | ID: mdl-35216675

Subject(s)

COVID-19 , Neoplasms , Antibody Formation , COVID-19/prevention & control , COVID-19 Vaccines , Humans , Neoplasms/genetics , RNA, Messenger , Vaccination

ABSTRACT

Subject(s)

Subject(s)

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL